BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Sanofi India Ltd.’s Q3 CY20 revenues de-grew 11.9% YoY to Rs 687 crore mainly due to the full impact of divesture of a few products to Zentiva (Ankleshwar slump sale) and continued impact of Covid-19 on some therapies.
Ebitda margins improved 547 basis points YoY to 28.0% due to lower other expenditure, better gross margins.
Subsequently, Ebitda grew 9.5% YoY to Rs 192 crore. Reported profit after tax grew 5% YoY to Rs 133 crore.
Delta vis-a-vis Ebitda was due to lower tax rate in Q3 CY19.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR